Related Experiment Video
Updated: Jul 7, 2026
05:10
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
Recent and anticipated novel drug approvals (Q2 2026 through Q1 2027)
Rachel Joseph1, Michelle Sabbah1, Farah Barada1
1Northwestern Medicine, Chicago, IL, USA.
Summary
Health-system pharmacists can prepare for upcoming novel drug approvals, including advanced therapies for genetic disorders and oncology. This review highlights key medications anticipated to impact hospital and clinic care in the coming year.
Area of Science:
- Pharmacology
- Drug Development
- Health-System Pharmacy
Background:
- Health-system pharmacists are vital for managing formularies and resources.
- Monitoring the pharmaceutical pipeline is essential for optimizing patient care with new therapies.
Purpose of the Study:
- To provide pharmacists with information on new and anticipated novel drug approvals.
- To support resource allocation and clinical program optimization for emerging treatments.
Main Methods:
- Review of selected novel drugs awaiting US Food and Drug Administration (FDA) approval.
- Analysis focused on drugs expected to have significant clinical and financial impact.
Main Results:
- Anticipated drug approvals span the second quarter of 2026 through the first quarter of 2027.
- The pipeline includes novel therapies for rare genetic disorders, immunologic diseases, targeted oncology, and gene therapies.
Conclusions:
- Novel therapies are continually enhancing the drug development pipeline.
- Pharmacists are key to integrating these advancements into healthcare settings.
Related Concept Videos
01:26FDA Approved Drugs: Changes to Approved Drugs
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:26Drug Administration and Therapy Phases: Overview
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
01:25Drug Regulation
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...